Osimertinib is a mutant-selective EGFR-TKI that targets treatment-naïve EGFR mutant lung cancers and cancers that acquire a gatekeeper EGFR T790M mutation after treatment with EGFR-TKIs6,7. Here, EGFR is linked to lung carcinoma.